The Massey Cancer Center provides support for development of approved, translational clinical trial concepts based on laboratory discoveries of MCC Scientific Program investigators, into innovative early phase clinical trials. Following PRMC review and approval of these trials, Massey Cancer Center will also provide support for the conduct, analysis and reporting of the trial. Massey members and associate members are eligible to apply for MCC support by developing and submitting translational concepts for review by the Clinical Trial Concept Review Committee. Approved concepts receive support of MCC Scientific Writer and other clinical research support to develop a preliminary protocol and budget for submission to external sponsors for drug supply and partial funding. Once drug supply and external support level have been identified, the preliminary concept and the proposed budget the concepts will undergo a second CTCRC review for final approval for full protocol development and conduct if PRMC approval for activation is forthcoming. If a need for additional preclinical studies needed to procure drug supply a request for funding support with a budget may be included with the resubmission.

We are now soliciting submissions of a proposed concepts for translational trials, which is to be submitted no later than October 14, 2016 for review at the October 25th meeting of the CTCRC.

- The laboratory work providing the rationale and justification for the concept should be sufficiently mature and complete to be move to the clinic. If additional preclinical work is required, consider submitted the project under the MCC Pilot Project program. Visit the MCC website for next funding cycle.
- Strong preference will be given to concepts backed by data published in higher impact peer reviewed journals.
- Trials that address non-traditional outcomes that could interface with cancer prevention and control studies are encouraged.
- The proposed trial's potential impact on the Cancer Center catchment area and cancer disparities must be addressed in the proposal.
- Concepts should be submitted using the Translational Clinical Trial Concept Submission Form. Manuscripts or publications related to the science should be cited. Investigators may include an Appendix up to 3 pages to provide unpublished, additional supporting data to the cited manuscripts.

Ranking will be based on novelty, scientific merit, feasibility, the value of the trial to the cancer clinical research priorities of the Massey Cancer Center, and the proximity to trial initiation. Collaborations between clinical investigators with basic laboratory researchers and investigators in social and behavioral health and other cancer control research are strongly encouraged.

Interested members should submit a completed Translational Clinical Trial Concept Submission Form to Martha Wellons at mwellons@vcu.edu by October 14, 2016. The Announcement and Submission Form are available on the MCC website at https://www.massey.vcu.edu/research/funding/mcc-clinical-trial-concept-program/.